



G-GOC Trials



Pedro T. Ramirez, MD
Professor

David M. Gershenson Distinguished Professor in Ovarian Cancer Research
Director of Enhanced Recovery After Surgery Program
Director of Minimally Invasive Research & Education
Department of Gynecologic Oncology & Reproductive Medicine

ConCerv-G-GOC



Cervical Cancer-Conservative Management

Cone/Simple Hysterectomy + SLN Only

Stage IA2-IB1 (<2cm) LVSI (-)

Study Design: Prospective Phase II

Sponsor(s): None

Planned No. of patients: 100


Current accrual: 81

Other important information:

14 Sites Overall


Primary: MD Anderson

ConCerv-G-GOC



- MD Anderson, USA (K. Schmeler) 
- IDC, Colombia (G. Rendon) 
- INCAN, Mexico (D. Cantu) 
- Barretos, Brazil (G. Fontes) 
- INEN, Peru (A. Lopez) 
- Instituto de Ginecologia, Argentina (M. Riege) 
- Hospital Italiano, Argentina (M. Perrotta) 
- Royal Women's, Australia (O. McNally) 
- Nebraska Methodist, USA (D. Crotzer) 
- Hospital Britanico, Argentina (A. Maya) 
- Chulalongkorn University, Thailand (T. Manchana) 
- Hospital Erasto Gaertner, Brazil (A. Tsunoda) 
- Instituto Brasileiro Controle de Cancer, Brazil (A. Lopes) 
- Astorga Clinica de Oncologia, Colombia (R. Pareja) 

LACC-G-GOC



Cervical Cancer-Open vs. MIS Radical Hysterectomy

Stage IA2-IB1

Study Design: Prospective Randomized (50/50)

Sponsor(s): None

Planned No. of patients: 740


Current accrual: 636

Other important information:


29 Sites Overall

Primary: MD Anderson

Recruitment Tracker



Recruitment Tracker



Consort Statement

LACC Consort Statement as at 24th October 2017

